Sandoz Pregabalin Capsule 150 mg
Pregabalin
Prescription medication
Korea Sandoz Co., Ltd.
MFDS item code 201504305 · Approved 2015.06.30
This product's status changed to Approval withdrawn on 2023.06.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to treat pain caused by peripheral and central neuropathic conditions in adults, and is used as an adjunct for partial seizures in epilepsy patients with or without secondary generalized symptoms. It is also effective in relieving pain associated with fibromyalgia. This medication helps improve symptoms of various nerve-related disorders.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If needed, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (age 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Use is not recommended in children under 12 years of age or adolescent patients aged 12 ~17 years because sufficient safety and efficacy data are not available.
During treatment with this medication, patients should be closely monitored for suicidal thoughts or behavior, depression, and abnormal changes in mood and behavior as it is an anticonvulsant. This medication should not be administered to patients with hypersensitivity to the active ingredient pregabalin or those with specific genetic lactose intolerance. Patients with diabetes may require dose adjustments for blood sugar control due to weight gain, and administration should be stopped immediately if symptoms of angioedema occur. Elderly patients may experience symptoms such as dizziness, drowsiness, and confusion, so caution is needed when starting treatment; visual disturbances may also occur. Abrupt discontinuation of this medication may result in withdrawal symptoms such as insomnia, headache, and anxiety; thus, dosage should be reduced gradually. Given the potential for drug abuse and dependence, patients with a history of mental health disorders should be monitored closely. Patients with reduced kidney function may require dose adjustments, and caution should be used when administering to patients with heart failure. The risk of respiratory depression may be increased when used with other CNS depressants, particularly opioids. This medication should not be given to pregnant women, especially in the early stages, unless there are exceptional circumstances, due to the risk of fetal deformities; women of childbearing age should use effective contraception. During breastfeeding, as this medication is excreted in breast milk, it may be necessary to consider discontinuation of breastfeeding or the medication itself. This medication may cause dizziness and drowsiness; thus, patients should avoid engaging in hazardous activities such as driving or operating machinery until they understand how the medication affects them. Severe skin reactions have been rarely reported, so patients should immediately inform healthcare providers if skin rashes or symptoms occur. In case of overdose, symptoms such as confusion, drowsiness, depression, or seizures may occur, and treatment may require procedures such as hemodialysis if necessary. Particular caution is needed for children, elderly, and patients with reduced kidney function, and the medication should be stored out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a sealed container. It is also advisable to store the medication at temperatures between 15°C and 30°C, avoiding extreme heat or cold, to maintain its effectiveness and safety.
White or almost white powder in a hard capsule with a white upper part and white lower part
28 capsules (7 capsules/PTPX4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin
Prescription medication
Korea Sandoz Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.